New drug before lung cancer surgery shows promise in early trial
NCT ID NCT07402070
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called IBI363 given before surgery for people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the drug helps shrink or eliminate the tumor before the operation. About 10 participants will receive IBI363, and researchers will monitor safety and how well the cancer responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE II-III NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China